Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ROS1 |
Variant | rearrange |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | ROS1 rearrange indicates an unspecified rearrangement of the ROS1 gene. |
Associated Drug Resistance | |
Category Variants Paths |
ROS1 mutant ROS1 rearrange |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05589818 | Phase II | Pembrolizumab | Pembrolizumab for Advanced NSCLC and PS 2-3 | Recruiting | USA | 0 |
NCT04693468 | Phase I | Axitinib + Talazoparib Crizotinib + Talazoparib Palbociclib + Talazoparib | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | Recruiting | USA | 0 |
NCT05313009 | Phase Ib/II | Sotorasib + TH-4000 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | Terminated | USA | 0 |
NCT03696212 | Phase Ib/II | Grapiprant + Pembrolizumab | Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma | Terminated | USA | 0 |
NCT04863248 | Phase II | Docetaxel + Trilaciclib Docetaxel | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) | Terminated | USA | 0 |
NCT02321501 | Phase I | Ceritinib + Everolimus | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT06680050 | Phase II | Ceralasertib + Durvalumab | Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (AUSTRAL) (AUSTRAL) | Not yet recruiting | ITA | CHE | 0 |
NCT03469960 | Phase III | Ipilimumab + Nivolumab | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE) | Active, not recruiting | FRA | 0 |
NCT03786692 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Bevacizumab + Carboplatin + Pemetrexed Disodium | Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | Recruiting | USA | 0 |
NCT03317496 | Phase II | Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | Terminated | USA | ITA | HUN | GBR | ESP | CZE | CAN | AUS | 0 |
NCT03915951 | Phase II | Binimetinib + Encorafenib | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | Active, not recruiting | USA | NLD | ITA | ESP | 1 |
NCT04725188 | Phase II | Docetaxel Docetaxel + MK-7684A MK-7684A | Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) | Completed | USA | POL | ITA | ISR | FRA | FIN | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 5 |
NCT03977194 | Phase III | Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY) | Active, not recruiting | FRA | 0 |
NCT05788926 | Phase I | TG6050 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | Recruiting | FRA | 0 |
NCT04866017 | Phase III | Durvalumab BGBA1217 + Tislelizumab Tislelizumab | A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Terminated | USA | ESP | AUS | 2 |
NCT05676749 | Phase I | Aldesleukin + C-TIL051 + Pembrolizumab | C-TIL051 in Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05255302 | Phase II | Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL) | Recruiting | FRA | 0 |
NCT02568267 | Phase II | Entrectinib | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 6 |
NCT04892953 | Phase II | Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | Recruiting | USA | 0 |
NCT03334617 | Phase II | Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab | Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) | Active, not recruiting | USA | ISR | FRA | ESP | DEU | CAN | AUT | 1 |
NCT03425006 | Phase II | Itacitinib + Pembrolizumab | Pembrolizumab and Itacitinib (INCB039110) for NSCLC | Terminated | USA | 0 |
NCT04223596 | Phase II | Brigatinib | Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK) | Active, not recruiting | ESP | 0 |
NCT06561386 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 7 |
NCT06088771 | Phase Ib/II | Cemiplimab + Dupilumab | Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | Recruiting | USA | 0 |
NCT05769075 | Phase I | TY-2136b | A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations | Recruiting | USA | 0 |
NCT03087448 | Phase Ib/II | Ceritinib + Trametinib | Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT04683250 | Phase Ib/II | Vepafestinib | Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET)) | Recruiting | USA | 1 |
NCT05650879 | Phase I | ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |
NCT05398094 | Phase II | Sotorasib | Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (MERIT-lung) | Recruiting | ESP | 0 |
NCT05215340 | Phase III | Pembrolizumab Datopotamab deruxtecan + Pembrolizumab | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT05785767 | Phase II | Cemiplimab Cemiplimab + Fianlimab | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | TUR | ISR | CAN | AUS | 5 |
NCT05555732 | Phase III | Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT03308942 | Phase II | Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib | Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | Completed | USA | 0 |
NCT06120075 | Phase I | AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) | Recruiting | USA | 0 |
NCT03516981 | Phase II | MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | Active, not recruiting | USA | POL | ITA | IRL | GBR | ESP | CHE | CAN | AUS | 7 |
NCT02473497 | Expanded access | Crizotinib | Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients | No longer available | USA | 0 |
NCT04884282 | Phase II | Docetaxel + OSE 2101 Docetaxel Nivolumab + OSE 2101 | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED) | Recruiting | ITA | FRA | ESP | 0 |
NCT04151563 | Phase Ib/II | Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab | A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy | Withdrawn | USA | ROU | POL | NOR | NLD | GRC | DNK | BEL | ARG | 1 |
NCT03993873 | Phase Ib/II | Elzovantinib | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) | Active, not recruiting | USA | FRA | ESP | 1 |
NCT06119581 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium | A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) | Recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 7 |
NCT03840902 | Phase II | Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | NLD | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 4 |
NCT04623775 | Phase II | Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ROU | POL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 3 |
NCT04621188 | Phase II | Lorlatinib | Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) | Recruiting | FRA | 0 |
NCT05777603 | Phase I | Aztreonam + Pembrolizumab + Vancomycin | Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06552234 | Phase II | Repotrectinib | Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC (REPOROS) | Not yet recruiting | FRA | 0 |
NCT04940637 | Phase II | Dostarlimab-gxly + Niraparib | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001) | Recruiting | ITA | 0 |
NCT06162572 | Phase Ib/II | Cemiplimab + S095029 Cemiplimab + Sym024 Cemiplimab + Sym023 Cemiplimab | Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | Recruiting | USA | ROU | ITA | HUN | GBR | FRA | ESP | BRA | BEL | AUT | AUS | ARG | 3 |
NCT05815173 | Phase I | Ladarixin + Sotorasib | Ladarixin With Sotorasib in Advanced NSCLC | Recruiting | USA | 0 |
NCT03322566 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | Completed | USA | TUR | ITA | ISR | IRL | HUN | GBR | ESP | CAN | AUS | 4 |
NCT04793815 | FDA approved | Pembrolizumab | Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) | Completed | CAN | 0 |
NCT05815186 | Phase II | Ladarixin + Sotorasib | Ladarixin With Sotorasib in Advanced NSCLC - Phase II | Withdrawn | USA | 0 |
NCT03175224 | Phase Ib/II | Vebreltinib | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) | Recruiting | USA | ITA | HUN | GBR | FRA | FIN | ESP | CAN | AUS | 4 |
NCT05000710 | Phase II | Durvalumab Durvalumab + Tremelimumab Tremelimumab | Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung) | Active, not recruiting | ISR | 0 |
NCT04984811 | Phase II | Atezolizumab + NT-I7 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | Active, not recruiting | USA | 0 |
NCT03709147 | Phase II | Carboplatin + Metformin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Metformin + Pembrolizumab + Pemetrexed Disodium | Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME) | Unknown status | ITA | 0 |
NCT04956692 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | Active, not recruiting | USA | TUR | ROU | POL | HUN | FRA | ESP | BRA | 8 |
NCT05118789 | Phase Ib/II | NUV-520 | A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT03896074 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT) | Unknown status | ITA | 0 |
NCT06364917 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | Not yet recruiting | USA | 0 |
NCT04585815 | Phase Ib/II | Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | Active, not recruiting | USA | GBR | BEL | AUS | 1 |
NCT04862780 | Phase Ib/II | BLU-945 BLU-945 + Osimertinib | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Active, not recruiting | USA | NLD | GBR | FRA | ESP | CAN | 4 |
NCT05358548 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab | ATATcH Alternating Treatment Plans for Advanced Cancer | Recruiting | USA | 0 |
NCT06116682 | Phase II | Amivantamab-vmjw | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Recruiting | USA | 0 |
NCT04270591 | Phase Ib/II | SCC244 | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | Recruiting | USA | 2 |
NCT03827850 | Phase II | Erdafitinib | FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) | Terminated | DEU | 0 |
NCT04512430 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | Terminated | ESP | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 1 |
NCT02696993 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04921358 | Phase III | Docetaxel Sitravatinib + Tislelizumab | Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Terminated | AUS | 1 |
NCT04108026 | Phase II | Durvalumab | Immunotherapy in Patient With Poor General Condition (SAVIMMUNE) | Active, not recruiting | FRA | 0 |
NCT01970865 | Phase II | Lorlatinib Crizotinib | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | Completed | USA | ITA | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 5 |
NCT03840915 | Phase Ib/II | Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp alfa + Docetaxel Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Nab-paclitaxel | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | Completed | USA | FRA | BEL | 0 |
NCT04603807 | Phase III | Entrectinib Crizotinib | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | Recruiting | TUR | SWE | SVK | ROU | NLD | LBN | ITA | HRV | GRC | FRA | ESP | DEU | BRA | 6 |
NCT05469178 | Phase Ib/II | Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06099782 | Phase II | MK-3475A Pembrolizumab | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | Active, not recruiting | USA | TUR | POL | NZL | FRA | AUS | ARG | 3 |
NCT03631706 | Phase II | Bintrafusp alfa Pembrolizumab | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | NLD | ITA | GRC | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 6 |
NCT05709821 | Phase Ib/II | Pembrolizumab IMM60 IMM60 + Pembrolizumab | IMM60 and Pembrolizumab in Melanoma and NSCLC | Terminated | USA | GBR | ESP | 0 |
NCT03793179 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 1 |
NCT04655976 | Phase II | Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly Docetaxel + Dostarlimab-gxly | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 6 |
NCT05144997 | FDA approved | Lorlatinib | Lorlatinib Continuation Study | Active, not recruiting | USA | FRA | ESP | 5 |
NCT06644768 | Phase Ib/II | Pembrolizumab DS-3201b + Pembrolizumab | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Recruiting | USA | BRA | ARG | 3 |
NCT05568212 | Phase II | Durvalumab Durvalumab + Olaparib | Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab | Recruiting | ITA | 0 |
NCT04811001 | Phase II | Dacomitinib Osimertinib | Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND) | Recruiting | ITA | 0 |
NCT06173505 | Phase Ib/II | Carboplatin + Pemetrexed Disodium + XmAb20717 Carboplatin + Pembrolizumab + Pemetrexed Disodium | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Recruiting | USA | POL | NLD | GRC | ESP | BEL | 3 |
NCT04776447 | Phase II | Atezolizumab + Carboplatin + Paclitaxel | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO) | Active, not recruiting | ESP | 0 |
NCT03664024 | Phase II | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium | Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782) | Completed | USA | ISR | HUN | ESP | CAN | 0 |
NCT04746924 | Phase III | Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DEU | BRA | AUS | ARG | 9 |
NCT06593522 | Phase II | AMG193 | A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC | Not yet recruiting | USA | CAN | AUS | 0 |
NCT04738487 | Phase III | Pembrolizumab MK-7684A | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) | Active, not recruiting | USA | TUR | ROU | HUN | CAN | BRA | 17 |
NCT06357533 | Phase III | Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) | Recruiting | USA | TUR | POL | ITA | HUN | GBR | ESP | DEU | CAN | BRA | BEL | AUT | AUS | 6 |
NCT04250246 | Phase II | Ipilimumab + Nivolumab Guadecitabine + Ipilimumab + Nivolumab | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1) | Not yet recruiting | ITA | 0 |
NCT04033354 | Phase III | Carboplatin + Nab-paclitaxel + Serplulimab Carboplatin + Nab-paclitaxel | A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC | Active, not recruiting | USA | TUR | POL | 4 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT02927340 | Phase II | Lorlatinib | A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | Unknown status | USA | 0 |
NCT04292119 | Phase Ib/II | Binimetinib + Lorlatinib Crizotinib + Lorlatinib | Lorlatinib Combinations in Lung Cancer | Unknown status | USA | 0 |
NCT03088930 | Phase II | Crizotinib | Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT00585195 | Phase I | Crizotinib + Itraconazole Crizotinib + Rifampin | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) | Completed | USA | AUS | 2 |
NCT05541822 | Phase II | ABN401 | To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | Recruiting | USA | 2 |
NCT05984277 | Phase III | Carboplatin + MEDI5752 + Pemetrexed Disodium Carboplatin + MEDI5752 + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02) | Recruiting | USA | TUR | SVK | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT05757492 | Phase Ib/II | CHS-006 + Toripalimab-tpzi | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04929041 | Phase II | Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin | Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | Recruiting | USA | 0 |
NCT03965468 | Phase II | Carboplatin + Durvalumab + Paclitaxel | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS) | Recruiting | NLD | ITA | ESP | CHE | 0 |
NCT04084717 | Phase II | Crizotinib | Study of Crizotinib for ROS1 and MET Activated Lung Cancer | Recruiting | CAN | 0 |
NCT05005273 | Phase II | Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | Completed | USA | TUR | POL | ITA | ISR | FRA | ESP | DEU | BEL | AUS | ARG | 1 |
NCT03975114 | Phase II | Durvalumab + Tremelimumab Durvalumab | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) | Recruiting | ITA | 0 |
NCT05064280 | Phase II | Lenvatinib Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
NCT03829319 | Phase III | Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium | Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) | Active, not recruiting | USA | TUR | POL | NZL | ISR | GBR | FRA | ESP | DEU | CAN | AUS | ARG | 5 |
NCT05501665 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Pembrolizumab | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | Recruiting | USA | 0 |
NCT03468985 | Phase II | Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT03322540 | Phase II | Pembrolizumab Epacadostat + Pembrolizumab | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | Completed | USA | TUR | POL | ITA | ISR | IRL | GBR | EST | ESP | DNK | CHE | CAN | AUS | 5 |
NCT03904108 | Phase II | Ramucirumab | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy | Terminated | USA | 0 |
NCT05935774 | Phase II | Atezolizumab + Trabedersen | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT06472245 | Phase III | OSE 2101 Docetaxel | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA) | Recruiting | USA | ROU | GBR | FRA | ESP | BEL | 1 |
NCT05687266 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Durvalumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR) | Active, not recruiting | USA | TUR | SWE | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | AUT | 8 |
NCT05311709 | Phase II | Sotorasib | Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities (SOLUCOM) | Recruiting | NOR | 0 |
NCT03472560 | Phase II | Avelumab + Axitinib | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | Terminated | USA | POL | ITA | HUN | ESP | 3 |
NCT04263051 | Phase II | Nivolumab + UCPVax | Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax) | Active, not recruiting | FRA | 0 |
NCT04105270 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium | RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial | Recruiting | USA | 0 |
NCT03559049 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04625699 | Phase II | Durvalumab + Tremelimumab | Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment | Withdrawn | 0 | |
NCT05899608 | Phase III | Pembrolizumab Ivonescimab | Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients | Recruiting | USA | CAN | 0 |
NCT05715229 | Phase II | Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT) | Recruiting | USA | 0 |
NCT04526782 | Phase II | Docetaxel Binimetinib + Encorafenib | ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) | Recruiting | FRA | 0 |
NCT06532032 | Phase Ib/II | Amivantamab-vmjw + Docetaxel | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail) | Recruiting | USA | TUR | 1 |
NCT03417037 | Phase III | Linrodostat + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer | Withdrawn | USA | TUR | ITA | GRC | FRA | ESP | DEU | CZE | CHE | CAN | BRA | AUT | AUS | 4 |
NCT05570825 | Phase II | Pembrolizumab + SX-682 | SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05012254 | Phase II | Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain) | Active, not recruiting | ESP | 0 |
NCT04265534 | Phase II | Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) | Terminated | USA | 0 |
NCT05048797 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | Recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | 7 |
NCT04800822 | Phase I | PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 | PF-07284892 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02279433 | Phase I | Taletrectinib | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Completed | USA | 0 |
NCT03093116 | Phase Ib/II | Repotrectinib | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Recruiting | USA | POL | NLD | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 7 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Completed | USA | NZL | FRA | ESP | DNK | 1 |
NCT05703555 | Phase II | SAR408701 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION) | Withdrawn | NLD | 0 |
NCT06140836 | Phase III | Repotrectinib Crizotinib | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | FRA | ESP | DEU | CHE | CAN | BRA | AUT | ARG | 6 |
NCT05401786 | Phase II | Cemiplimab Ipilimumab | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO) | Recruiting | NLD | 0 |
NCT05241873 | Phase Ib/II | BLU-451 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Active, not recruiting | USA | CAN | 3 |
NCT06627647 | Phase III | AZD2936 + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Not yet recruiting | USA | TUR | HUN | GBR | ESP | DEU | CAN | BRA | BEL | ARG | 7 |
NCT06116786 | Phase I | Cetrelimab + JNJ-86974680 | A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | Recruiting | USA | ESP | DEU | 1 |
NCT06031688 | Phase II | Tepotinib Ramucirumab + Tepotinib | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Recruiting | USA | 0 |
NCT05212922 | Phase II | Toripalimab-tpzi + YH001 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001) | Withdrawn | AUT | AUS | 3 |
NCT04467723 | Phase Ib/II | Atezolizumab + Pirfenidone | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | Recruiting | USA | 0 |
NCT06074588 | Phase III | Docetaxel SKB264 Pemetrexed Disodium | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Recruiting | USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 11 |
NCT06656598 | Phase II | Carboplatin + Cemiplimab + Paclitaxel | Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer (SPORADIC) | Not yet recruiting | FRA | 0 |
NCT06094296 | Phase II | Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Completed | USA | AUS | 0 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Pembrolizumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT03591731 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC) | Active, not recruiting | FRA | 0 |
NCT04585477 | Phase II | Durvalumab | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | Recruiting | USA | 0 |
NCT03064854 | Phase I | Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab Canakinumab + Carboplatin + Spartalizumab Carboplatin + Paclitaxel + Spartalizumab Cisplatin + Pemetrexed Disodium + Spartalizumab Cisplatin + Gemcitabine + Spartalizumab | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BEL | 3 |
NCT02879617 | Phase II | Durvalumab | A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients | Completed | USA | 0 |
NCT04005144 | Phase I | Binimetinib + Brigatinib | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04832854 | Phase II | Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Gemcitabine + Tiragolumab Atezolizumab + Cisplatin + Gemcitabine + Tiragolumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | Active, not recruiting | USA | ESP | CHE | AUS | 1 |
NCT05007769 | Phase II | Atezolizumab + Nogapendekin alfa inbakicept + Ramucirumab | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN) | Withdrawn | 0 | |
NCT05598853 | Phase I | Ipilimumab + Nivolumab | Intrathecal Double Checkpoint Inhibition (IT-IO) | Recruiting | CHE | 0 |
NCT04827576 | Phase II | Docetaxel + Hu5F9-G4 | Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) | Terminated | USA | POL | GBR | FRA | ESP | 0 |
NCT04547504 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE) | Active, not recruiting | FRA | 0 |
NCT05781308 | Phase II | Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE) | Active, not recruiting | FRA | 0 |
NCT03166631 | Phase I | BI 891065 + Ezabenlimab BI 891065 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | Terminated | USA | 0 |
NCT03994796 | Phase II | Abemaciclib GDC-0084 Entrectinib | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | Recruiting | USA | 0 |
NCT05631574 | Phase I | BMF-219 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | Recruiting | USA | 1 |
NCT03996473 | Phase Ib/II | Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride | Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases | Terminated | USA | NLD | ESP | BEL | 0 |
NCT05840770 | Phase II | Cemiplimab | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03348904 | Phase III | Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT05746481 | Phase II | Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab | Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | Recruiting | USA | 0 |
NCT06635824 | Phase III | Docetaxel GEN1046 + Pembrolizumab | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | Recruiting | USA | 2 |
NCT04995523 | Phase Ib/II | AZD2936 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01) | Recruiting | USA | NLD | GBR | FRA | ESP | DNK | BRA | BEL | AUS | 9 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | POL | GBR | FRA | CAN | AUS | 2 |
NCT04140500 | Phase I | RO7247669 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | TUR | ISR | GBR | ESP | DNK | 5 |